Whitepapers

TAU – The Next Target For Neurology Focus On IONS and SGMO

TAU – The Next Target For Neurology Focus On IONS and SGMO

TAU – The Next Target For Neurology Focus On IONS and SGMO. Two neurology scientific meetings have taken place this Fall and focused on hot new targets for neurological drug development – notably, beta-amyloid and tau.

0 comments

ESPR – Esperion Hits a Grand Slam With Triple Therapy Data

ESPR continues to execute at a Big Pharma/Bio level with a small, emerging Company focus. After the successful trial, the Company raised $150 million at $49 per share. NDA Filing And Enrollment Ahead of Schedule.

0 comments

MDCO: ORION – Inclisiran Rising In The PCSK9 Sky

The Medicines Company (MDCO) presented the details of the ORION-1 Phase II trial interim results of 501 patients given MDCO-PCSK-9si at a Late-Breaker Session at the AHA. MDCO presented the details of the ORION-1 Phase II trial interim results of 501 patients given MDCO-PCSK-9si at a Late-Breaker Session at the AHA.

0 comments

A Brief Look At Shorts

A Brief Look At Shorts (ACAD, ANTH, BMRN, INCY, IONS, MDCO, NVAX, NKTR, PCRX, ZIOP (for subscribers only).

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Thank you.
0 comments

SENTIMENT – A CORE MTSL INVESTMENT METHODOLOGY

February 19, 2015 The most recent reading of the CNN/Money Fear and Greed Indicator has entered the “Extreme Greed” range. While very short-term in nature, it represents the level of expectations investors have in stocks and today that level is quite high. It all suggests that while stocks may still move higher, they are likely to[…]

0 comments

The Comparables

During the past year or so, biotech experienced an unprecedented number of companies going public. Over that period, we have added two such names to our portfolio – PCRX (2012) and FPRX (2014). A handful of these stocks have achieved remarkable valuations…

0 comments

Biotech Fund Managers – What The Pros Do Every Year

August 21, 2014 The Medical Technology Stock Letter (“MTSL”) prides itself on identifying exciting small companies that will become leaders in their respective fields over time. We emphasize “over time” because that is the nature of drug development and compounded returns of successful biotech stocks over the years vastly exceed that of the overall market. […]

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Thank you.
0 comments

A BRIEF IMMUNE-ONCOLOGY UPDATE

June 12, 2014 ASCO 2014 – Immune Oncology Rises to the Top – As many expected, immune oncology (I-O) was all the rage at the recently concluded American Society of Clinical Oncology (ASCO) meeting.  While it is widely acknowledged that before ASCO, Bristol was the leader in the space followed by Merck, and Roche.  At[…]

0 comments

NOT YOUR FATHER’S PLATFORMS

MTSL published Issue #753 “Plentiful Platforms” on April 25, 2012. Most of our platform recommendations have made significant progress since then, and our subscriber base has grown substantially as well.

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Thank you.
0 comments

Bios Go From 1st To Worst, Is A Bottom Near? New Recommendation

Five Prime Therapeutics’ (FPRX) Protein Platform Technology Ready For Prime Time – Five Prime is a classic early-stage platform company with, in our view, a proprietary and powerful technology based on management’s broad experience and unique understanding of proteins.

0 comments

Graduation Day – the New Tiers: ISIS makes it to 1st Tier, NVAX & SGMO Join Tier 2

SuperBios: Amgen, Biogen, Celgene & Gliead – These four companies (a.k.a. The Four Horsemen) have emerged as the leaders of the biotechnology sector and have become true global players that, due to their size and innovation, can compete evenly with the Big Phama companies on the traditional pharmaceutical fronts.

0 comments

PCYC – Introducing The Autoimmune Program, The Next Chapter

PCYC – Understanding The New CLL Label & Introducing The Autoimmune Program – Raising BUY LIMIT and TARGET PRICE

0 comments

INCY & ISIS – THE NEXT PHASE

CHASING INCY – INCY Poised to Emerge as Oncology Powerhouse, Raising BUY LIMIT – The biggest driver of INCY’s value over the last year, and in our view, going forward has been the emergence of their oncology pipeline.

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Thank you.
0 comments

2013 MTSL Portfolio Review – We’re #1!

According to the Hulbert Financial Digest (HFD), the Trader’s Portfolio of the Medical Technology Stock Letter was the #1 performing Portfolio of 2013 – with a return of 215%. This was out of more than 500 portfolios tracked by Hulbert.

0 comments

INCY’s IDO and A Visit to Novavax

INCY’s IDO & Cancer Immunotherapy – Treating cancer with immunotherapy has become one of the major “Hot New Classes” over the last year as the science, compounds and subsequent studies have demonstrated the ability to significantly extend the lives of cancer patients.

0 comments

WHAT BIOINVEST CAN DO FOR YOU

What can BioInvest do for you? BioInvest focuses on the most important topics, trends and therapies affecting the biotech sector and the MTSL portfolio. Learn more about and subscribe to our Medical Technology Stock Letter today.

0 comments

ORAL ARGUMENTS

Historically, classic biotech companies developed monoclonal antibodies and proteins as new therapies for hard-to-treat conditions. There have been multiple examples of blockbuster successes (e.g., EPO, anti-TNF antibodies, HGH, human insulin, etc.) leading the past 30+ years to create the Biotechnology sector.

To access this post, you must have an active subscription to the Medical Technology Stock Letter. Thank you.
0 comments

THE NEW CLASSES ARE IN SESSION

The pharmaceutical and biotechnology industries have gone through periods of blockbuster drug classes, which has often resulted in one or more leading drugs catapulting the respective company’s growth rates and, in many cases, market capital, to the very top of the industry.

0 comments

HIT ‘EM WHERE THEY AIN’T

Unlike most Wall Street analysts, we find no need to continue to raise limits/target prices just because a stock has done what we expect it to. Our initial recommendations are based on the stocks not yet discounting what we believe are improving and/or undervalued fundamentals.

0 comments

INCY KNOWS JAKS

INCY – KNOWS JAKS– RAISING BUY LIMIT & TARGET – INCB039110 Shows Promise with Proof-of-Concept Data in Both Psoriasis & RA, MF Next Up at ASH

0 comments